JP2017535613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535613A5 JP2017535613A5 JP2017545858A JP2017545858A JP2017535613A5 JP 2017535613 A5 JP2017535613 A5 JP 2017535613A5 JP 2017545858 A JP2017545858 A JP 2017545858A JP 2017545858 A JP2017545858 A JP 2017545858A JP 2017535613 A5 JP2017535613 A5 JP 2017535613A5
- Authority
- JP
- Japan
- Prior art keywords
- sublingual
- disorder
- preparation according
- riluzole
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 7
- 229960004181 riluzole Drugs 0.000 claims 7
- 210000000214 mouth Anatomy 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 231100000862 numbness Toxicity 0.000 claims 4
- 206010031009 Oral pain Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010013142 Disinhibition Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002996 emotional effect Effects 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000005976 liver dysfunction Effects 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010000060 Abdominal distension Diseases 0.000 claims 1
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010219 Compulsions Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 206010018286 Gingival pain Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- 206010029897 Obsessive thoughts Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034568 Peripheral coldness Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010037180 Psychiatric symptoms Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 239000004376 Sucralose Substances 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 231100000870 cognitive problem Toxicity 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 201000003636 hereditary ataxia Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 208000027753 pain disease Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000003989 repetitive behavior Effects 0.000 claims 1
- 208000013406 repetitive behavior Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 1
- 235000019408 sucralose Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083094P | 2014-11-21 | 2014-11-21 | |
| US62/083,094 | 2014-11-21 | ||
| PCT/US2015/061114 WO2016081472A1 (en) | 2014-11-21 | 2015-11-17 | Sublingual formulation of riluzole |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139429A Division JP2021001173A (ja) | 2014-11-21 | 2020-08-20 | リルゾールの舌下製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535613A JP2017535613A (ja) | 2017-11-30 |
| JP2017535613A5 true JP2017535613A5 (Direct) | 2018-11-01 |
| JP6753860B2 JP6753860B2 (ja) | 2020-09-09 |
Family
ID=55085882
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545858A Active JP6753860B2 (ja) | 2014-11-21 | 2015-11-17 | リルゾールの舌下製剤 |
| JP2020139429A Pending JP2021001173A (ja) | 2014-11-21 | 2020-08-20 | リルゾールの舌下製剤 |
| JP2023015640A Pending JP2023065398A (ja) | 2014-11-21 | 2023-02-03 | リルゾールの舌下製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139429A Pending JP2021001173A (ja) | 2014-11-21 | 2020-08-20 | リルゾールの舌下製剤 |
| JP2023015640A Pending JP2023065398A (ja) | 2014-11-21 | 2023-02-03 | リルゾールの舌下製剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11660267B2 (Direct) |
| EP (3) | EP3616686B8 (Direct) |
| JP (3) | JP6753860B2 (Direct) |
| KR (2) | KR102811263B1 (Direct) |
| CN (1) | CN107249567B (Direct) |
| AU (2) | AU2015350148B2 (Direct) |
| BR (1) | BR112017010423B1 (Direct) |
| CA (1) | CA2967662A1 (Direct) |
| CY (1) | CY1122469T1 (Direct) |
| DK (1) | DK3220891T3 (Direct) |
| EA (1) | EA038518B1 (Direct) |
| ES (2) | ES2882783T3 (Direct) |
| HR (1) | HRP20191892T8 (Direct) |
| HU (1) | HUE046869T2 (Direct) |
| IL (2) | IL278188B2 (Direct) |
| LT (1) | LT3220891T (Direct) |
| MX (1) | MX368838B (Direct) |
| PH (1) | PH12017500934B1 (Direct) |
| PL (1) | PL3220891T3 (Direct) |
| PT (1) | PT3220891T (Direct) |
| RS (1) | RS59490B1 (Direct) |
| SG (1) | SG11201703896QA (Direct) |
| SI (1) | SI3220891T1 (Direct) |
| WO (1) | WO2016081472A1 (Direct) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102173463B1 (ko) | 2016-10-11 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적 분해용 화합물 및 방법 |
| JP7354123B2 (ja) * | 2018-02-21 | 2023-10-02 | エイアイ・セラピューティクス・インコーポレーテッド | アピリモドとグルタミン酸作動薬を用いた併用療法 |
| US12364687B2 (en) * | 2018-05-27 | 2025-07-22 | Biohaven Therapeutics Ltd. | Use of riluzole oral disintegrating tablets for treating diseases |
| JP2021534160A (ja) * | 2018-08-16 | 2021-12-09 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
| IL292359A (en) * | 2019-10-22 | 2022-06-01 | Arvinas Operations Inc | Prostate cancer treatment methods |
| TW202208345A (zh) | 2020-05-09 | 2022-03-01 | 美商亞文納營運公司 | 雙官能性化合物的製造方法、該雙官能性化合物的超純形式、及含彼之劑型 |
| WO2022076321A1 (en) * | 2020-10-05 | 2022-04-14 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103635A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
| KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
| DE69429119T2 (de) | 1993-07-09 | 2002-07-18 | R.P. Scherer Corp., Troy | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| JP2001507222A (ja) * | 1996-12-20 | 2001-06-05 | ニュートリノウヴァ・ニュートリション・スペシャルティーズ・アンド・フード・イングリーディエンツ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 極めて強力な甘味料の混合物の甘味力を向上させそして味を向上させる方法 |
| CA2281473C (en) | 1997-02-20 | 2007-01-16 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| WO1999004758A1 (en) | 1997-07-25 | 1999-02-04 | Elan Corporation Plc | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
| AU767154B2 (en) | 1998-11-20 | 2003-10-30 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
| ATE289800T1 (de) * | 1998-12-09 | 2005-03-15 | Chiron Corp | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems |
| FR2787028B1 (fr) | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
| US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| CA2463495C (en) | 2001-10-12 | 2011-05-24 | Elan Pharma International Ltd. | Compositions having a combination of immediate release and controlled release characteristics |
| AU2003211051A1 (en) | 2002-02-13 | 2003-09-04 | Michael K. Weibel | Drug dose-form and method of manufacture |
| EP2316469A1 (en) * | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| WO2004105756A2 (en) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| WO2005084377A2 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| WO2007074472A2 (en) | 2005-12-27 | 2007-07-05 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
| JP5269894B2 (ja) | 2007-06-27 | 2013-08-21 | ハンミ ファーム． シーオー．， エルティーディー． | 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置 |
| WO2010009279A1 (en) * | 2008-07-15 | 2010-01-21 | University Of Medicine And Dentistry Of New Jersey | Methods and compositions for treating alzheimer's disease |
| US8518031B2 (en) | 2008-10-31 | 2013-08-27 | The Invention Science Fund I, Llc | Systems, devices and methods for making or administering frozen particles |
| US8731842B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| WO2010096869A1 (en) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart |
| EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| US9241933B2 (en) * | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| PT2560631E (pt) * | 2011-03-01 | 2014-02-24 | Pharnext | Terapia à base de baclofeno e acamprosato de distúrbios neurológicos |
| CN109316480A (zh) | 2011-07-13 | 2019-02-12 | 赛特凯恩蒂克公司 | 组合als疗法 |
| CA2864008C (en) | 2012-03-01 | 2020-04-21 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
| US20180153862A1 (en) | 2014-11-21 | 2018-06-07 | Biohaven Pharmaceutical Holding Company Limited (B | Sublingual administration of riluzole |
| AU2016226463B2 (en) * | 2015-03-03 | 2020-06-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzole prodrugs and their use |
-
2015
- 2015-11-17 CA CA2967662A patent/CA2967662A1/en active Pending
- 2015-11-17 KR KR1020237031525A patent/KR102811263B1/ko active Active
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/en active Active
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 EP EP21169884.0A patent/EP4039247B1/en active Active
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 IL IL278188A patent/IL278188B2/en unknown
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active Active
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/en active Active
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/en not_active Ceased
- 2015-11-17 PH PH1/2017/500934A patent/PH12017500934B1/en unknown
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
-
2019
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-25 US US17/079,498 patent/US12121609B2/en active Active
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
-
2024
- 2024-10-21 US US18/921,046 patent/US20250114301A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535613A5 (Direct) | ||
| JP2017535612A5 (Direct) | ||
| US10369182B2 (en) | Compositions and methods for treating insomnia and other sleep related disorders | |
| ES2730088T3 (es) | Formulaciones para el tratamiento de trastornos de la boca, la garganta y las vías respiratorias | |
| NO20013859L (no) | Cyklooksygenase-2 inhibitoriske medikamenter med rask inntreden av terapeutisk virkning | |
| JP2023076465A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| JP2010522137A5 (Direct) | ||
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| JP2010535805A5 (Direct) | ||
| WO2010116385A3 (en) | Pharmaceutical compositions for alleviating unpleasant taste | |
| JP2010520185A5 (Direct) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| CN102895472B (zh) | 一种治疗口腔溃疡的外用组合药物及其制备方法 | |
| JP2016505050A5 (Direct) | ||
| JP2011500589A5 (Direct) | ||
| CN103623373B (zh) | 预防晕动病的内服中药 | |
| CN104116968A (zh) | 一种具有镇静安神治疗失眠的中药制剂 | |
| JP2021066751A (ja) | 経口用医薬組成物 | |
| ES2742034T3 (es) | Composición farmacéutica que contiene flurbiprofeno | |
| CN103100020B (zh) | 一种治疗牙痛的中药制剂 | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| Nogueira et al. | 44265 Oral coenzyme Q10: The new authority in skin aging. Results of a randomized, double-blind, placebo-controlled trial in elderly women | |
| CN103520648A (zh) | 一种治疗牙龈炎的中药组合物 | |
| CN103751499A (zh) | 一种治疗口腔溃疡的中药组合物 | |
| CN101926879B (zh) | 一种治疗牙痛的中药组合物 |